Premium
Evolution of renal function under direct‐acting antivirals treatment for chronic hepatitis C: A real‐world experience
Author(s) -
Tsai MingChao,
Lin ChunYen,
Hung ChaoHung,
Lu ShengNan,
Tung ShuiYi,
Chien RongNan,
Lin ChihLang,
Wang JingHoung,
ChienHung Chen,
Chang KuoChin,
Hu TsungHui,
Sheen IShyan
Publication year - 2019
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13193
Subject(s) - medicine , renal function , regimen , gastroenterology , urology , chronic hepatitis , cohort , multivariate analysis , immunology , virus
Renal toxicity of direct‐acting antivirals (DAAs) in chronic hepatitis C (CHC) patients has not been well‐characterized. The aim of this study was to assess renal safety of DAAs in an Asian CHC patient cohort. Data from CHC patients (n = 1536) treated with DAAs were used in this retrospective study. Serial estimated glomerular filtration rate (eGFR) at pretreatment (1‐year prior to treatment), baseline, end of treatment (EOT), and 12 weeks after treatment (SVR 12 ) was evaluated. While a significant decrease in eGFR from baseline to EOT (84.8 → 81.8 mL/min/1.73 m 2 , P < .001) was observed; subsequently, a slight rise at SVR 12 (84.3 mL/min/1.73 m 2 ) was also evident. Changes in eGFR after DAA treatment were similar to those seen in PrOD, DCV/ASV and GZP/EBV regimens, except in the SOF‐based regimen wherein eGFR remained unchanged from EOT to SVR 12 , especially in liver transplant recipients. Multivariate analysis revealed that age >65 years (OR = 1.862, P = .011), baseline eGFR ≥ 60 mL/min/1.73 m 2 (OR = 2.684, P = .023), and liver transplant (OR = 3.894, P = .001) were independent risk factors for deteriorating renal function. In conclusion, DAA treatment led to a significant decline in eGFR at EOT but was followed by a slight rise at 12 weeks after treatment. A similar trend was observed with PrOD, DCV/ASV and GZP/EBV, but not in SOF‐based regimens. As age >65 years, baseline eGFR ≥ 60 mL/min/1.73 m 2 and liver transplantation are significant risk factors for deterioration in renal function, we strongly advice close monitoring of renal function in these populations.